Prof. Nicholas Paton trained in Medicine and Infectious Diseases in Cambridge, Sydney and London, and in Epidemiology at the London School of Hygiene and Tropical Medicine. From 1997 to 2005 he worked as Head of Department at the National HIV Referral Centre in Singapore and, in addition to clinical care responsibilities, developed a Centre for Research in HIV and Communicable Diseases. From 2006 to 2011 he worked at the UK MRC Clinical Trials Unit where he was the Chief Investigator of large HIV treatment trials such as PIVOT (a trial of a PI-monotherapy strategy done at 45 clinical sites in the UK); and EARNEST (testing options for second-line therapy in over 1200 patients in 5 countries in sub-Saharan Africa).
He currently holds a joint appointment as Professor of Infectious Diseases at the National University of Singapore and at the London School of Hygiene and Tropical Medicine. He is the Chief Investigator of the NADIA trial (comparing dolutegravir with darunavir and comparing maintenance of tenofovir versus switching to zidovudine in second-line therapy, done in 7 sites in Uganda, Kenya and Zimbabwe) and the scientific lead of the CARES trial (comparing long acting cabotegravir/rilpivirine with standard combination ART at 8 sites in Uganda, Kenya and South Africa). In Singapore he leads a programme of TB trials focused on trials of host-directed therapies for TB and exploring novel TB trial outcome measures; and is the Chief Investigator on the TRUNCATE-TB trial (a strategy trial of 2 months of treatment for drug-susceptible TB done across a network of 18 sites in Asia and Africa).